📊 AVTX Key Takeaways
Investment Thesis
Avalo Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and deteriorating financial condition. The company has depleted its revenue to zero with a 77.1% YoY decline, burning $37.2M in operating cash flow annually against only $27.0M in cash reserves, indicating a critical liquidity runway of less than 9 months. With persistent operating losses of $53.2M, negative returns on equity and assets exceeding -50%, and substantial long-term debt, the company faces imminent financing pressure or potential insolvency.
AVTX Strengths
- Strong current ratio of 14.28x suggests adequate short-term liquidity relative to current liabilities
- Moderate debt-to-equity ratio of 0.16x indicates conservative leverage relative to equity base
- Positive insider activity with 9 Form 4 filings in last 90 days may suggest management confidence
AVTX Risks
- Critical cash runway of approximately 8 months at current burn rate with only $27.0M cash against $37.2M annual operating cash burn
- Complete revenue collapse to $0 (77.1% YoY decline) indicating failed commercialization or pipeline setbacks
- Persistent operating losses of $53.2M and net losses of $64.5M with negative ROE of -70.5% and ROA of -51.6% demonstrating severe unprofitability
- High interest coverage ratio of -83.8x indicates inability to service debt from operations
- Unsustainable business model requiring immediate capital raise or strategic alternatives to avoid dilution or bankruptcy
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway forecast
- Clinical trial progress updates and pipeline advancement milestones
- Any fundraising announcements or debt restructuring activities
- Operating cash flow trajectory and quarterly cash position
AVTX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 14.28x current ratio provides a solid financial cushion.
AVTX Profitability Ratios
AVTX vs Healthcare Sector
How Avalo Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AVTX Balance Sheet & Liquidity
AVTX 5-Year Financial Trend
5-Year Trend Summary: Avalo Therapeutics, Inc.'s revenue has declined by 71% over the 5-year period, indicating business contraction. The most recent EPS of $-113.58 indicates the company is currently unprofitable.
AVTX Growth Metrics (YoY)
AVTX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $210.0K | $-2.19 |
| Q3 2024 | $236.0K | $210.0K | $-2.83 |
| Q2 2024 | N/A | -$8.2M | $-14.07 |
| Q1 2024 | N/A | -$10.0M | $-141.00 |
| Q3 2023 | $236.0K | $3.2M | $-0.11 |
| Q2 2023 | $643.0K | -$8.2M | $-0.59 |
| Q1 2023 | $475.0K | -$10.0M | $-0.85 |
| Q3 2022 | $1.4M | $3.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AVTX Capital Allocation
AVTX SEC Filings
Access official SEC EDGAR filings for Avalo Therapeutics, Inc. (CIK: 0001534120)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 18, 2026 | 4 | xslF345X06/form4-03182026_080310.xml | View → |
| Mar 2, 2026 | 4 | xslF345X05/form4-03022026_090313.xml | View → |
| Mar 2, 2026 | 4 | xslF345X05/form4-03022026_090329.xml | View → |
| Mar 2, 2026 | 4 | xslF345X05/form4-03022026_090303.xml | View → |
| Mar 2, 2026 | 4 | xslF345X05/form4-03022026_090334.xml | View → |
❓ Frequently Asked Questions about AVTX
What is the AI rating for AVTX?
Avalo Therapeutics, Inc. (AVTX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVTX's key strengths?
Strong current ratio of 14.28x suggests adequate short-term liquidity relative to current liabilities. Moderate debt-to-equity ratio of 0.16x indicates conservative leverage relative to equity base.
What are the risks of investing in AVTX?
Critical cash runway of approximately 8 months at current burn rate with only $27.0M cash against $37.2M annual operating cash burn. Complete revenue collapse to $0 (77.1% YoY decline) indicating failed commercialization or pipeline setbacks.
What is AVTX's revenue and growth?
Avalo Therapeutics, Inc. reported revenue of $0.0.
Does AVTX pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
Where can I find AVTX SEC filings?
Official SEC filings for Avalo Therapeutics, Inc. (CIK: 0001534120) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVTX's EPS?
Avalo Therapeutics, Inc. has a diluted EPS of $-5.47.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.